Table 1.
Primary patient characteristics
| MM1 | MM2 | MM3 | |
|---|---|---|---|
| Age (years) | 64 | 60 | 65 |
| Gender | female | female | female |
| Ig subtype | IgD | IgG | IgA |
| Light-chain subtype | lambda | lambda | kappa |
| Prior therapies | 6 | 7 | 4 |
| -lenalidomide | yes | yes | yes |
| -bortezomib | yes | yes | yes |
| -dexamethasone | yes | yes | yes |
| -carfilzomib | yes | yes | yes |
| -pomalidomide | yes | yes | yes |
| -ASCT | no | yes | yes |
| -daratumumab | yes | yes | no |
| -cytoxan | yes | yes | no |
| BM PC infiltration | 80% | 90% | 80% |
| Evidence of EM-MM | no | no | no |
| Cytogenetics | +1q22, +3, +7, +9, −13, +15, XX | −1p, +3, +7, −9, +11, −13, +14, −17, XX | +1, +3, +5, +7, −8, +9, +11, −13, +15,XX |
| Snapshot-NGS | 7.9% NRAS Q61R
7.1% BRAF V600E |
BRAF D594N TP53 R267W (variant allele frequency not reported) |
34.0% NRAS Q61H 20.3% BRAF D594N |
| Best IMWG response on treatment | stable disease (SD) | progressive disease (PD | very good partial response (VGPR) |